Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Binimetinib in TNBC
NCT03106415Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of binimetinib in triple-negative breast cancer (TNBC), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 35 days and Objective Response Rate at 3 years. Started Sep 2017; status: completed.
02
Drugs
binimetinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03106415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106415.